Inspired from these points of view, we have evaluated the guiding role of elevated pretreatment serum CEA levels for use of ACT in ypTis-3N0 rectal cancer using the Surveillance, Epidemiology, and End Results (SEER) database. Here, CEACAM5 is linked to rectal cancer.